Dina L. Masi - 09 Dec 2025 Form 4 Insider Report for INTEGRATED BIOPHARMA INC (INBP)

Reporting relationship: Chief Financial Officer
Issuer ticker: INBP
Reported as of: 09 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Dec 2025, 17:09:03 UTC
Prior SEC filing: 22 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Dina L Masi

Key filing fact

Dina L. Masi filed Form 4 for INTEGRATED BIOPHARMA INC (INBP) on 10 Dec 2025.

Key facts

This page summarizes Dina L. Masi's Form 4 filing for INTEGRATED BIOPHARMA INC (INBP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Dec 2025, 17:09.

Change

Previous filing in this sequence was filed on 22 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001345281 Primary reporting owner

Masi Dina

Relationship: Chief Financial Officer
Address: 14 LEXINGTON WAY, LONG VALLEY
Signature: /s/ Dina L Masi
Signature date: 10 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +140,000
Change %
Price: $0.000000
Shares after: 140,000
Date: 09 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 140,000
Exercise price: $0.3100
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable in three equal annual installments with the first installment vesting on December 9, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .